CDKN2A and pancreatic neuroendocrine tumor: For example, we find subclonal driver mutations in MEN1 in pancreatic neuroendocrine tumors (6 of 30), TP53 in prostate and breast cancers (4 of 12 and 5 of 59, respectively), and CDKN2A in pancreatic adenocarcinomas (5 of 42).